Q-omics provides the consensus-scored IGLJ3 profile across patient tissues and cancer cell-line models. IGLJ3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLJ3 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, IGLJ3 RNA expression shows 12,569 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, UCEC, and LSCC as cancer lineages where IGLJ3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLJ3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLJ3 survival associations across molecular data types. IGLJ3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLJ3 RNA expression–survival associations across cancer types. High IGLJ3 expression shows unfavorable associations in UVM, KIRP, UCS and KIRC, but favorable associations in HNSC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLJ3 RNA expression.
This table summarizes IGLJ3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for IGLJ3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLJ3 shows lower tumor expression in BRCA, KICH and STAD and higher tumor expression in UCEC, LUAD and COAD. The UCEC box plot shows higher IGLJ3 RNA expression in tumor versus normal tissue (log2 FC = +3.605, t-test p = .013).
This table shows molecular features associated with IGLJ3 in patient tissues and cancer cell lines. In patient samples, IGLJ3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
